Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q3Scopus Q2KCI Q3
- 저널
- KOREAN JOURNAL OF INTERNAL MEDICINE38(2) · pp.238 · 2023
- 피인용
- Web of Science 2Scopus 1KCI 0
- FWCI (Scopus)
- 0.09
- JCR IF
- JCR 2022 2.4
- ISSN
- 1226-3303
저자
- Cho, Hee Jeong제1저자Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Jo, Jae-CheolUniv Ulsan, Ulsan Univ Hosp, Dept Hematol & Oncol, Coll Med, Ulsan, South Korea
- Lee, Yoo JinUniv Ulsan, Ulsan Univ Hosp, Dept Hematol & Oncol, Coll Med, Ulsan, South Korea
- Lee, Myung WonChungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Hematol Oncol, Coll Med, Daejeon, South Korea
- 김도영Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Hematol Oncol, Sch Med, Busan, South Korea
- 신호진Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Hematol Oncol, Sch Med, Busan, South Korea
- Im, Sung NamInje Univ, Dept Hematol Oncol, Haeundae Paik Hosp, Busan, South Korea
- Lee, Ji HyunDong A Univ Hosp, Dept Hematol Oncol, Busan, South Korea
- Bae, Sung HwaDaegu Catholic Univ, Daegu Catholic Univ Hosp, Dept Hematol Oncol, Sch Med, Daegu, South Korea
- Do, Young RokKeimyung Univ, Dept Hematol Oncol, Sch Med, Daegu, South Korea
- Lee, Won SikInje Univ, Dept Hematol Oncol, Busan Paik Hosp, Busan, South Korea
- Kim, Min KyungKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Jung, JinaKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Lee, Jung MinKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Kim, Ju-HyungKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Baek, Dong WonKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Sohn, Sang-KyunKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
- Moon, Joon Ho교신저자Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
초록
Background/Aims: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for predicting survival outcomes of patients treated with daratumumab. Methods: Between 2018 and 2021, the medical records of patients with relapsed/refractory MM (RRMM) treated with daratumumab monotherapy at 10 centers in South Korea were reviewed. We collected the ALC data at pre-infusion (D0), day 2 after the first infusion (D2), and prior to the third cycle of daratumumab therapy (D56). Results: Fifty patients who were administered at least two cycles of daratumumab were included. Overall response rate was 54.0% after two cycles of daratumumab treatment. On D2, almost all patients experienced a marked reduction in ALC. However, an increase in ALC on D56 (ALCD56) was observed in patients with non-progressive disease, whereas failure of ALC recovery was noted in those with progressive disease. Patients with ALCD56> 700/mu L (n = 39, 78.0%) had prolonged progression-free survival (PFS) and overall survival (OS) than those with ALCD56 <= 700/mu L (median PFS: 5.8 months vs. 2.6 months, p = 0.025; median OS: 24.1 months vs. 6.1 months, p = 0.004). In addition, ALCD56 >700/mu L was a significant favorable prognostic factor for PFS (hazard ratio [HR], 0.22; p = 0.003) and OS (HR, 0.23; p = 0.012). Conclusions: Increase in ALC during daratumumab treatment was significantly associated with prolonged survival outcomes in patients with RRMM. The ALC value can predict clinical outcomes in patients treated with daratumumab.
키워드
Multiple myelomaDaratumumabLymphocyte countBiomarkersSurvival analysisSURVIVALMONOTHERAPYCELLSCRITERIATHERAPYIMPACTRISKCD38
식별자
- Scopus EID
- 2-s2.0-85149427784
- WoS UID
- 000925347900001
- KCI
- ART002931941



로그인
연구물 목록으로